Last updated on September 2018

Phase 2b Study to Evaluate the Efficacy and Safety of GBR 830 in Adults With Moderate to Severe Atopic Dermatitis


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Moderate to Severe Atopic Dermatitis
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Male or female subjects aged 18 years with physician diagnosis of atopic dermatitis for >1 year as defined by American Academy of Dermatology Consensus Criteria.
  • Atopic dermatitis involvement of 10% of body surface area and IGA score of 3 at screening and baseline.
  • EASI score of 12 at screening or 16 at baseline.
  • IGA score of 3 at screening and baseline (on the 0 to 4 IGA scale, in which 3 is moderate and 4 is severe)
  • Baseline Pruritus Numerical Rating Scale (NRS) score for maximum itch intensity 3 over the previous 24 hours.

Exclusion Criteria:

  • Pregnant or lactating women.
  • Prior treatment with GBR 830
  • Treatment with biologics
  • Systemic corticosteroids, immunosuppressive/immunomodulatory drugs or phototherapy within 4 weeks of baseline
  • Active chronic or acute infection requiring systemic treatment

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.